Reviewing MiMedx Group (NASDAQ:MDXG) and BioNTech (NASDAQ:BNTX)Defense World · Oct 17, 2026
MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026GlobeNewsWire · Oct 14, 2026
MiMedx Group, Inc (NASDAQ:MDXG) Receives Consensus Rating of “Moderate Buy” from AnalystsDefense World · Oct 6, 2026
Compugen (NASDAQ:CGEN) versus MiMedx Group (NASDAQ:MDXG) Head-To-Head ComparisonDefense World · Sep 24, 2026
Protagonist Therapeutics (NASDAQ:PTGX) & MiMedx Group (NASDAQ:MDXG) Head-To-Head ReviewDefense World · Sep 24, 2026
MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification MatterGlobeNewsWire · Sep 23, 2026MiMedx Group, Inc. specializes in creating and supplying allografts derived from placental tissue, serving a diverse range of medical fields. The company employs its unique, patented PURION process to treat human placental tissues, a method crucial for manufacturing allografts that preserve the natural biological characteristics and essential regulatory proteins of the original tissue. This exclusive and patented processing technique incorporates both aseptic procedures and a final sterilization step, ensuring product safety and efficacy.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 29, 2026 | -$0.05 | -$0.05 | Miss |
| Apr 29, 2026 | -$0.07 | -$0.05 | Beat |
| Feb 25, 2026 | $0.09 | $0.14 | Beat |
| Oct 29, 2025 | $0.07 | $0.15 | Beat |
| Jul 30, 2025 | $0.06 | $0.10 | Beat |
| Apr 30, 2025 | $0.06 | $0.06 | Beat |